Mount Yale Investment Advisors LLC Has $793,000 Position in Medtronic plc (NYSE:MDT)

Mount Yale Investment Advisors LLC lifted its stake in shares of Medtronic plc (NYSE:MDT - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,923 shares of the medical technology company's stock after purchasing an additional 3,017 shares during the period. Mount Yale Investment Advisors LLC's holdings in Medtronic were worth $793,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Highline Wealth Partners LLC acquired a new position in Medtronic during the 3rd quarter worth approximately $27,000. Darwin Wealth Management LLC bought a new position in Medtronic in the 3rd quarter valued at approximately $27,000. J. Stern & Co. LLP acquired a new stake in Medtronic in the third quarter valued at approximately $30,000. Finally, Kieckhefer Group LLC bought a new stake in shares of Medtronic during the fourth quarter worth $40,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Stock Down 1.4 %

MDT stock traded down $1.26 during mid-day trading on Friday, reaching $90.74. The company had a trading volume of 7,214,570 shares, compared to its average volume of 7,751,809. Medtronic plc has a fifty-two week low of $75.96 and a fifty-two week high of $93.08. The company has a market capitalization of $116.35 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.59 and a beta of 0.83. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84. The firm has a fifty day simple moving average of $84.29 and a 200 day simple moving average of $85.91.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion during the quarter, compared to analysts' expectations of $8.27 billion. During the same quarter in the previous year, the business earned $1.25 earnings per share. The firm's revenue was up 5.2% compared to the same quarter last year. Analysts forecast that Medtronic plc will post 5.45 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Friday, December 27th were given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Friday, December 27th. Medtronic's dividend payout ratio is presently 85.63%.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of research analyst reports. Robert W. Baird cut their price objective on shares of Medtronic from $96.00 to $93.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 20th. JPMorgan Chase & Co. dropped their price target on shares of Medtronic from $99.00 to $96.00 and set a "neutral" rating on the stock in a research report on Friday, November 15th. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a report on Monday, November 18th. Sanford C. Bernstein raised their target price on Medtronic from $96.00 to $97.00 and gave the company an "outperform" rating in a report on Wednesday, November 20th. Finally, Royal Bank of Canada upgraded Medtronic from a "sector perform" rating to an "outperform" rating and upped their price target for the stock from $98.00 to $105.00 in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of "Hold" and a consensus price target of $95.00.

Insider Transactions at Medtronic

In other news, EVP Brett A. Wall sold 12,437 shares of the company's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $90.00, for a total value of $1,119,330.00. Following the completion of the transaction, the executive vice president now directly owns 40,979 shares in the company, valued at approximately $3,688,110. This represents a 23.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.20% of the company's stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.